Valentina Cauda is Associate Professor at the Department of Applied Science and Technology (DISAT), Politecnico di Torino, co-founder of the Interdepartmetal laboratory PolitoBIOMed Lab and head of the TrojaNanoHorse lab (in brief TNHLab) located at DISAT. See more details at https://areeweb.polito.it/TNHlab/.
Thanks to her ERC Starting Grant project (TrojaNanoHorse, GA 678151), started in March 2016, she now leads a multidisciplinary research group of 18 people, including chemists, biologists, physics, engineers and nanotechnologists. Her main research topic is about theranostic nanomaterials, from wet synthesis, chemical functionalization and physical-chemical characterization of metal oxide nanomaterials covered by lipidic bilayer from both artificial and natural origins, aimed for drug delivery, tumor cell targeting, bio-imaging. Metal oxide nanomaterials, like zinc oxide, mesoporous silica, titania and metal (gold, silver) nanostructures, as well as liposomes and cell-derived extracellular vesicles, are investigated.
Valentina Cauda graduated in Chemical Engineering in 2004 at Politecnico di Torino and then received her Ph.D. in Material Science and Technology in 2008. After a short period at the University of Madrid, she worked as a post-doc at the University of Munich, Germany on nanoparticles for drug delivery and tumor cell targeting. From 2010 to 2015 she worked as Senior Post Doc at the Istituto Italiano di Tecnologia in Torino, and then she moved, as Associate Professor, to Politecnico di Torino. For her research results she received in 2010 the prize for young researchers at the Chemistry Department of the University of Munich, in 2013 the Giovedì Scienza award, in 2015 the Zonta Prize for Chemistry, and in 2017 the USERN Prize for Biological Sciences. She has 120 scientific publications and a Hirsch Factor of 37 (updated on April 2021). She holds 6 international patents about the use of metal oxide nanoparticles in nanomedicine.
Prof. Cauda is principal investigator of several industrial, national and international projects raising more than 2 M€ funds in all. The most relevant are a recently granted FET OPEN RIA MIMIC-KeY (GA N. 964386), the ERC Proof-of-Concept XtraUS N. 957563, a Marie-Slodowska Curie Action MINT N. 842964 (where she acts as supervisor of an incoming Post-Doc from abroad), and the ERC Starting Grant Trojananohorse N. 678151
Moein Moghimi is a Professor of Pharmaceutics and Nanomedicine (School of Pharmacy) and Affiliated Professor (Translational and Clinical Research Institute) at Newcastle University (UK); Adjoint Professor at the Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Denver Medical Center (USA); co-founder and advisory board member of S. M. Discovery Group Inc. (USA) and S. M. Discovery Group Ltd. (UK); Associate Editor of Molecular Therapy (The American Society of Gene and Cell Therapy, Cell Press); and Editor-in-Chief of the Journal of Nanotheranostics (Basel). His earlier appointments have included Professor and Chair in Pharmaceutics at the School of Medicine, Pharmacy and Health, Durham University, UK (2016- 2017); Full Affiliate Member/Professor at the Methodist Research Institute, Houston Methodist Hospital Systems, Houston, Texas, USA (2013-2017); Visiting Professor at Università Degli Studi Di Padova, Padova, Italy (2015); Professor of Nanomedicine (at the Department of Pharmacy), Professor of Pharmaceutical Nanotechology (at the NanoScience Center), and Founder/Director of the Center for Pharmaceutical Nanotechnology and Nanotoxiocology, University of Copenhagen, Denmark (2008-2016); and Honorary Professor of Nanomedicine at the Multidisciplinary Research Center, Shantou University, China (2008-2010).
Prof. Moghimi further serve on the editorial board of >20 international journals, including Advanced Drug Delivery Reviews , Journal of Controlled Release and Nanomedicine (UK) . Prof. Moghimi’s research is centred on fundamental and translational aspects of nanomedicine engineering and performance, with the overall goal of advancing fundamental understanding of biological barriers in relation to nanoparticle performance and safety, and within the context of precision medicine applicable to cancer, cardiovascular diseases, immune disorders, and disease of the central nervous system. As to date, Prof. Moghimi has published >300 research papers, reviews, book chapters, proceedings, and patents/patent applications. His work is highly cited in scientific literature (>22,500 citations as to date), and he is widely reported in general, local and professional press.
Hans Jörg Meisel MD PhD is now the Director of the Center of Neurosciences/Chair Dept.of Neurosurgery, BG-Clinic Bergmannstrost Halle-Donau-Universität Krems-Vrije Universiteit Medical Center (VUmc) Amsterdam-Translational Centre for Regenerative Medicine (TRM) Leipzig-President Regenerate Europe e.V.
In 1998 HJ. Meiselwas appointed to the Berufsgenossenschaftliche Clinic in Bergmannstrost Halle/Saale as Director of the Clinic for Neurosurgery. Every year his team of 10 surgeons carries out a minimum of 1800 surgeries in the area of cerebral and spinal diseases.Since September 2008 HJ. Meisel has been appointed as the Director of the Center of Neurosciences of the BG-Clinic Bergmannstrost Halle. HJ. Meiselsprimary focus in spine surgery and research is for the last 20 years in degenerative spinal diseases. Starting as inventor and designer of spinal implants for the intervertable space in cervical and lumbar in arthroplasty and fixation hedeveloped 1995the first biological disc repair transplantation system with autologus chondrocytes.HJ.Meisel served as a PI for the first randomized clinical trial to study this regenerative approach (EuroDisc) after running all preclinical evaluations at Emory Spine Center, Atlanta. Together with hisAtlantagroup theycontinued the preclinical and clinical work in disc regeneration with adiposed derived mesenchymal stem cells.As a founding member HJ. Meiselhelped to start the ETP Platform Nanomedicine for the European Commission. From 2003 to 2006 HJ.MeiselservedAOSpine Europeas a founding member andto develop a new teaching and course platform as a deputy on the neurosurgical side. (Intervertable Disc Course Davos, 2005; Strasbourg Course 2006; Cervical Course Palma de Mallorca, 2006)In 2005 HJ.Meiselco-founded the Translation Center for Regenerative Medicine at the University of Leipzig and supported there as an Executive Board member the preclinical affairs mentoring since the beginning 4 major spinal projects with the focus in regenerative disc repair and biomaterials financed by the German Ministry of Research (BMBF).In 2005 HJ. Meisel founded the European Network for Regenerative Medicine Regenerate Europewhich integrates 10 countries of the European Union that carry out research in the area of Regenerative Medicine and organized the Biospine Meetings (2002, 2007, 2010) and Regulatory Workshops for ATMPs and animal modeling (2010, 2012, 2014).In 2007 HJ.Meiselwas appointed by the Vreije University of Amsterdam to become a Visiting Professor in the Department of Orthopedic Surgery for the coordination of international research projects and the development of the European Master Degree in Regenerative Medicine.Currently there isrunningthe EU COST project Namabio “From nano to macro biomaterials (design, processing, characterization, modelling) and applications to stem cells regenerative orthopaedic and dental medicine” including 250 members in nanomaterial research and clinical application. In 2013 hebecame an Honorary Professor inthe Department for Health Sciences and Biomedicine at the Donau-University Krems (Austria).In 2013 he became an elected member of the AO Spine Knowledge Forum Degenerative and Biologics. In 2014 he was elected as chair of the European Technology Platform Nanomedicine (ETPN) Working Group of Nanotechnologies for Regenerative Medicine. HJ Meisel is active member of the EANS, SSE, ICRS, ISSLS, ISASS, AOSpine and others.
Paula Marques (born 1969) has a first degree in Chemistry (1993), a MSc in Chemistry and Physics Teaching (1997) and a PhD in Materials Science Engineering, with specialization in Biomaterials (2003) from the University of Aveiro (UA) in Portugal.
Paula is a Principal Researcher at TEMA – Centre for Mechanical Technology and Automation, Mechanical Engineering Department, UA. Currently is the Deputy-Director for Society and Social Responsibility in the Department of Mechanical Engineering and Sub-Director of the research unit TEMA (Centre of Mechanical Technology and Automation) board of Directors, responsible for new areas of specialization.
Her current research interests include the engineering and development of nanostructured multifunctional materials including graphene derivatives such as: (i) mechanical and electrical stimulus responsive 3D graphene-based scaffolds for tissue engineering; (ii) functional graphene-based macrostructures for water remediation; (iii) electrospun graphene/polymer fibres for photocatalysis; (iv) graphene-based materials as mechanical reinforcement of polymer matrixes.
Paula is author of 77+ original research or review papers in international journals (2900+ citations, h=28 – Scopus), about 7 book chapters, 2 books and 3 patents. Paula has been invited to review manuscripts from 30+ different international journals and to evaluate projects from Cost and Era-Net funding agencies. Paula supervised or co-supervised 10 MSc, 12 PhD students, and 8+ post-doctoral fellows. Since April 2019 she is coordinating a FET Open H2020 project, “NeuroStimSpinal: A Step Forward to Spinal Cord Injury Repair Using Innovative Stimulated Nanoengineered Scaffolds". She is also coordinating and co-coordinating several Portuguese Projects obtaining under competitive funding.
Regarding Paula’s pedagogical role, she is the teacher in charge for the 3rd cycle curricular unit Carbon Nanostructures, and teacher of the 2nd cycle curricular unit Technologies and Processes at Nanoscale.
Francesca Granucci obtained the PhD in Pharmacology and toxicology in 1996. She then performed the Post doc at the Dana Farber Cancer Institute – Boston. From 1997 to 2001 she worked as researcher at the Italian National Research in Milan and from 2001 to 2006 she worked as researcher at the University of Milano-Bicocca. In 2006 she obtained a position as Associate Professor and in 2016 as Full Professor at the University of Milano-Bicocca. She has pioneered systems biology approaches to study complex dynamic processes, such as host-pathogen interactions, the process of dendritic cell maturation and the role of dendritic cells in activating and controlling NK cell functions. More recently she focused her research activity on signalling events downstream of CD14/TLR4 within cells of the mammalian innate immune system and she identified some of the key functions played by the NFATc family of transcription factors activated in dendritic cells in response to PRR agonists.
Miriam Colombo obtained her Master degree in 2008 in Medicinal Chemistry and Technology at the University of Milano with experimental thesis in the Nanobiotechnology and she made the PhD in Biology in 2012 at the University of Milano-Bicocca. In 2010 she worked in the lab of prof. W. Parak, Marburg, Germany. In January 2009, she was awarded of a 12+24 months fellowship in the field of Medical Sciences. From September 2013 to September 2019 she was a researcher in Clinical Biochemistry (BIO/12), at the Dep. Biotechnology and Bioscience of University of Milano-Bicocca. From October 2019 she is associate professor of Clinical Biochemistry at the University of Milano-Bicocca. She is author of 93 scientific publications on peer-reviewed international journals. Official H-Index (Scopus): 29.
Nuno C. Santos was born in Lisbon, Portugal, in 1972. He graduated in Biochemistry from the Faculty of Science, University of Lisbon, in 1995, and received his PhD in Theoretical and Experimental Biochemistry in 1999 from the same University, although all the experimental work was conducted at Instituto Superior Técnico (Technical University of Lisbon) and University of California (Santa Barbara). Currently, he is Associate Professor with Habilitation of the Faculty of Medicine, University of Lisbon, and Head of the Biomembranes & Nanomedicine Unit at the Institute of Molecular Medicine (iMM). Among other distinctions, his research work was awarded with the Gulbenkian Prize for young researchers (2001), Dr. José Luis Champalimaud Prize – Basic Research (2004), Dr. José Luis Champalimaud Prize – Applied Research and Technology (2005) and the ULisboa – Caixa Geral de Depósitos Prize (2017). He is (co)author of 154 articles in per-reviewed international journals, which received more than 6800 citations (h-index 46 and i10-index 122, publishing since 1996), presenting a Web of Knowledge impact factor sum of 771.4 (average 5.1 per article). In addition to these publications, he (co)authored 10 articles in Portuguese scientific journals, 15 book chapters (mostly published outside Portugal, in English), 3 books (editor, published by Wiley, Springer and MDPI) and 2 international patents. Among different National and International research projects, he was the coordinator of a consortium funded by the 7th Framework Programme of the European Union (FP7), including 10 different research groups from Europe and Brazil. He is the President of the Portuguese Biophysical Society (SPBf) since 2015, member of the Executive Committee of the European Biophysical Societies’ Association (EBSA) since 2019, and the Director of the M2B-PhD Doctoral Program in Medical Biochemistry and Biophysics (involving 5 different institutions) since 2016. He has supervised 11 completed PhDs, 8 as main supervisor and 3 as co-supervisor.
Ernst Wagner is professor of Pharmaceutical Biotechnology at LMU and Munich Center of Nanoscience. Previously (1991-2001) he was Director Cancer Vaccines & Gene Therapy, Boehringer Ingelheim (first-in-world polymer-based human gene therapy trial in 1994), 1988 Junior Scientist/group leader at IMP Vienna and Medical Biochemistry Vienna Biocenter; 1985 -1987 postdoc at ETH Zurich, working on origin-of-life chemistry of sugar phosphates. He obtained a Ph.D. in chemistry, TU Vienna in 1985, is Academician of European Academy of Sciences, member of CRS College of Fellows, board member of German Society for Gene Therapy and Editor-in-Chief, Journal of Gene Medicine. He has authored 476 publications with > 44 444 citations on GS, h-index 105 (https://scholar.google.com/citations?user=-5wWbVAAAAAJ&hl=en)
Dr. Emmanuel Stratakis is a Research Director at the Institute of Electronic structure and laser (IESL) (www.iesl.forth.gr ) of the Foundation for Research and Technology—Hellas (FORTH) (www.forth.gr ). He received his Ph.D. in Physics from the University of Crete in 2001 from the Physics Department, University of Crete. After graduating, he joined as a visiting Researcher the IESL-FORTH working on the ultrafast laser engineering of materials and as an Adjunct Professor at the Department of Materials Science and Technology, University of Crete. In the fall semesters of 2006 and 2008, he was appointed as a visiting Researcher at the Department of Mechanical Engineering of the University of California, Berkeley. In 2007 he was elected Researcher at IESL-FORTH where he is leading the “Ultrafast Laser Micro- and Nano- processing” laboratory (http://stratakislab.iesl.forth.gr / https://www.iesl.forth.gr/en/research/ULNMP-Group). His research interests are in the fields of o (a) Laser-matter interaction; (b) Ultrashort pulsed laser processing of biomimetic surfaces ; (c) Laser processes for organic & hybrid electronics; (d) Laser engineeering and diagnostics of Graphene and related 2D materials ; (e) Advanced photonic processes in photovoltaic and energy storage devices; (f) Photo-assisted synthesis of nanocrystals; (g) Applications on non linear imaging in materials science and biology; (h) Laser assisted biofabrication for tissue engineering applications ; (i) Multipurpose 3D printing complemented with subtractive manufacturing. He has over 220 SCI publications and more than 8000 citations, h-index=48 (Scopus), and he has coordinated many National and EU grants. He has delivered more than 40 invited and keynote lectures and has been organizer and chair in major international scientific conferences. He has been an Editor of the journals ‘Optoelectronic Advances’, ‘Materials Today (Bio)’, ‘Applied Sciences’ and ‘International Journal of molecular Sciences. Since 2015, he is the Director of the Nanoscience Facility of FORTH, part of the NFFA-Europe EU Infrastructure, where he is a member of the General Assembly. He is a National expert in the High-Level Group of EU on Nanotechnologies, Advanced materials, Biotechnology, Advanced Manufacturing and Processing. He is a member of the Scientific Committee of COST. Since January 2020 he is the founder and Chief Executive Officer of Biomimetic (https://www.biomimetic.gr/).
Dr. James Moon is John Gideon Searle Associate Professor in the Department of Pharmaceutical Sciences and Biomedical Engineering at the University of Michigan, Ann Arbor. His interdisciplinary research program aims to develop novel biomaterials-based strategies to advance fundamental understanding of the immune system, with the ultimate goal of improving patients’ lives with effective vaccines and immunotherapies. His innovative research has led to a new class of vaccine nanoparticle system that can elicit unprecedented levels of T- and B-cell immune responses. Dr. Moon has published over 90 research articles, including those published in Nature Materials, Nature Medicine, Nature Biomedical Engineering, Nature Reviews Materials, and Science Translational Medicine. He has 16 pending/approved U.S. and international patent applications, and his novel nano-vaccine delivery technologies have led to two new start-up companies, Vedantra Pharmaceuticals and EVOQ Therapeutics. Dr. Moon contribution to the field has been recognized with numerous awards, including AAPS Emerging Leader Award, NSF CAREER Award, and DOD-CDMRP Career Development Award. Dr. Moon received his bachelor’s degree from the University of California, Berkeley, and his Ph.D. from Rice University, and he completed his postdoctoral training at MIT.
Mauro Comes Franchini received his degree in Industrial Chemistry at the University of Bologna in 1993 and PhD in Chemical Science, University of Bologna in 1996. Since from 1997 he is entitled with “Strategic Projects” CNR fellowship, later he becomes from 1998 as a researcher at the Faculty of Industrial Chemistry, Bologna. His International Experience is four months University of Nijmegen, The Netherlands, Dyson Perrins Laboratory and six months Oxford University, UK. He is the author of 87 articles published in international journals. Two WTO patents and 4 contributions to book's chapter and referee for several journals. He is the Member of the honorary editorial board of International Journal of Nanomedicine and the Member of the editorial board of Advances in Nanoparticles.
María de la Fuente Freire, a graduate in Pharmacy from the University of Santiago de Compostela (USC, 2001), completed her doctoral thesis in the Department of Pharmacy and Pharmaceutical Technology at the same institution (2001-2006), in the area of nano medicine and gene therapy. During this stage, she received two grants for predoctoral training, first from the Galician regional government (2001-2002), and then the Ministry of Education, FPU scholarship (2002-2006). She has also had two research residencies, one at the Institute of Applied Ophthalmology of the University of Valladolid (IOBA, 2003), and another at the University of Kuopio, Finland (2004). The results of her doctoral thesis led to her obtaining a PhD with European Doctorate accreditation, and her work was awarded the Prize for Best Doctoral Thesis “SPLC-CRS III and Eudragit Ph.D. Thesis Award”. In addition, she has generated several patents forming part of the intellectual property that led to the founding of the nano medicine division of Advancell S.L., in 2004.
Her post-doctoral training began at USC (2006-2007), as part of a project aimed at inhibiting invasion and metastasis processes, through the application of gene therapy and nanotechnology. Upon completion of this project, she moved to London (School of Pharmacy, University College of London, 2007-2011), participating in the preclinical development of nano-particle formulations, and the evaluation of new targets and therapeutic molecules for the treatment of tumours characterised by high aggressiveness (2007-2010). In addition, between 2008-2010 she was awarded a research grant by the Alfonso Martin Escudero Foundation. Part of her work during this stage was incorporated into the technology owned by the Nanomerics Ltd. spin-off. Her return to Spain was thanks to the Asociación Española Contra el Cáncer (Spanish Association Against Cancer), by whom she was made beneficiary of a contract for cancer researchers in the 2010 convocation.
In 2013, Dr. de la Fuente gained a Miguel Servet contract through competitive bidding, co-funded by the Carlos III Institute of Health (ISCIII) and the Galician Health Service (SERGAS), whose purpose is to incorporate doctors and translational research lines to public hospitals. With her research in therapeutic nano-oncology, nanotheranostics and translational processes to combat tumour spread and metastasis, she was integrated into the Translational Medical Oncology Group, where she directs the Laboratory of Nano-oncology and manages her own staff.
The scientific activity of Dr. de la Fuente is summarised in more than 35 publications in high impact journals, books, and book chapters. She participates in several European consortia, and is the principal researcher of two projects with national financing (ISCIII).
In the laboratory of Nano-oncology, the current team consists of the lead researcher and four researchers in predoctoral training stages. We also participate in the supervision of degree and masters final project work, and receive visiting researchers from other institutions.
Fabiana Arduini is Associate Professor at Department of Chemical Science and Technologies (Laboratory of Analytical Chemistry), University of Rome Tor Vergata . The research activity deals with the development of Bioassay and Biosensor systems, Electrochemical (bio)sensors, Electrochemical Mediators, Printed Electrodes, Sensors and Biosensors modified with Nanomaterials, Paper based (bio)sensors. The research activity was published in more than 80 articles in ISI peer-reviewed journals, among them with high impact factor in the analytical chemistry journal (e.g. Biosensor and Bioelectronics IF 8.173). H-index: 35, with 2814 total citations (Scopus, May 2019). She is author of more than 100 among poster and oral presentations at National and International congress, including plenary, keynotes and invited talk. She received in 2013 “Best Young Researcher” Award from the Analytical Chemistry Division of the Italian Chemical Society and in 2012 “Top cited author” for 2010-2011 on Biosensors and Bioelectronics journal (IF 6.451). She is the Coordinator of Interdivisional Sensor Group, Italian Chemical Society for the period 2019-2021. She is actually the Coordinator of European Project ERANETMED2-72-328 NanoSWS 2017-2020 “Integrated nanotechnologies for sustainable sensing water and sanitation”, BIAPTABONT project Ministry of Defence, INNOCONCRETE project within Executive Programme on Scientific and Technological Cooperation between Italian Republic and the Kingdom of Sweden for the years 2018-2020.
Gerard Tobias is a Research Scientist working at the Institut de Ciència de Materials de Barcelona (ICMAB-CSIC), where he leads research on “Nanoengineering of carbon and inorganic materials”. He received Bachelor of Chemistry (with Honours) from the Autonomous University of Barcelona (UAB, 2000) and Ph.D. with European mention (UAB, ICMAB, 2004). He was a research visitor at Ames Laboratory (USA) and EMAT (Belgium). Between 2004 and 2009 he was a postdoctoral researcher in the group of Prof. Malcolm L.H. Green at the University of Oxford. He has coordinated the FP7 European network RADDEL and has been recently granted an ERC Consolidator Grant (NEST).